QSAR Rationale of Matrix Metalloproteinase Inhibition Activity in a Class of Carboxylic Acid Based Compounds

References (56)

1. 1 Information Theory and an Extension of the Maximum Likelihood Principle [DOI]
2. 2 How Matrix Metalloproteinases Regulate Cell Behavior [DOI]
3. 3 Beware of q2! [DOI]
4. 4 Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations [DOI]
5. 5 Cross-Validatory Estimation of the Number of Components in Factor and Principal Components Models [DOI]
6. 6 An Essential Role for Ectodomain Shedding in Mammalian Development [DOI]
7. 7 Strategies for MMP inhibition in cancer: innovations for the post-trial era [DOI]
8. 8 Design and Therapeutic Application of Matrix Metalloproteinase Inhibitors [DOI]
9. 9 Practical Aspects of the Ligand-Binding and Enzymatic Properties of Human Serum Albumin. [DOI]
10. 10 Molecular Recognition of Protein−Ligand Complexes: Applications to Drug Design [DOI]
11. 11 Matrix metalloproteinase degradation of extracellular matrix: biological consequences [DOI]
12. 12 The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis [DOI]
13. 13 Membrane protein secretases [DOI]
14. 14 Shedding light on ADAM metalloproteinases [DOI]
15. 15 Matrix metalloproteinases degrade myelin basic protein [DOI]
16. 16 Expression of matrix metalloproteinase 9 (96‐kd gelatinase B) in human rheumatoid arthritis [DOI]
17. 17 Hydroxamic Acids as Pharmacological Agents [DOI]
18. 18 Matrix Metalloproteinases as Valid Clinical Target [DOI]
19. 19 Recent Developments in the Design of Specific Matrix Metalloproteinase Inhibitors aided by Structural and Computational Studies [DOI]
20. 20 PCA and PLS with very large data sets [DOI]
21. 21 Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis [DOI]
22. 22 Highly Selective and Orally Active Inhibitors of Type IV Collagenase (MMP-9 and MMP-2): N-Sulfonylamino Acid Derivatives [DOI]
23. 23 Variable Selection in QSAR Studies. II. A Highly Efficient Combination of Systematic Search and Evolution [DOI]
24. 24 6 Multivariate Data Analysis and Experimental Design in Biomedical Research [DOI]
25. 25 Three-Dimensional Quantitative Structure−Activity Relationships from Molecular Similarity Matrices and Genetic Neural Networks. 1. Method and Validations [DOI]
26. 26 Shedding light on sheddases: role in growth and development [DOI]
27. 27 Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.
28. 28 CP‐MLR/PLS Directed Structure‐Activity Modeling of the HIV‐1 RT Inhibitory Activity of 2,3‐Diaryl‐1,3‐thiazolidin‐4‐ones [DOI]
29. 29 A Bioinorganic Perspective on Matrix Metalloproteinase Inhibition [DOI]
30. 30 Discovery of Potent, Selective, and Orally Active Carboxylic Acid Based Inhibitors of Matrix Metalloproteinase-13 [DOI]
31. 31 Phase I and Pharmacokinetic Study of Prinomastat, a Matrix Metalloprotease Inhibitor [DOI]
32. 32 QSAR study about ATP-sensitive potassium channel activation of cromakalim analogues using CP-MLR approach [DOI]
33. 33 Topological descriptors in modeling the agonistic activity of human A3 adenosine receptor ligands: The derivatives of 2-chloro-N6-substituted-4′-thioadenosine-5′-uronamide [DOI]
34. 34 Combinatorial protocol in multiple linear regression/partial least-squares directed rationale for the caspase-3 inhibition activity of isoquinoline-1,3,4-trione derivatives [DOI]
35. 35 Structure determination and analysis of human neutrophil collagenase complexed with a hydroxamate inhibitor [DOI]
36. 36 Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790 [DOI]
37. 37 Parathyroid hormone-induced resorption in fetal rat limb bones is associated with production of the metalloproteinases collagenase and gelatinase B [DOI]
38. 38 Recent advances in the design of matrix metalloprotease inhibitors.
39. 39 A Combinatorial Approach to the Variable Selection in Multiple Linear Regression: Analysis of Selwood et al. Data Set – A Case Study [DOI]
40. 40 Analysis of the Binding of Hydroxamic Acid and Carboxylic Acid Inhibitors to the Stromelysin-1 (Matrix Metalloproteinase-3) Catalytic Domain by Isothermal Titration Calorimetry [DOI]
41. 41 Matrix metalloproteinase inhibitors reduce phorbol ester-induced cutaneous inflammation and hyperplasia [DOI]
42. 42 H-31 human breast cancer cells stimulate type I collagenase production in osteoblast-like cells and induce bone resorption [DOI]
43. 43 Synthesis and identification of conformationally constrained selective MMP inhibitors [DOI]
44. 44 A quantitative structure-activity relationship study on serotonin 5-HT6receptor ligands: indolyl and piperidinyl sulphonamides [DOI]
45. 45 Modelling of serotonin reuptake inhibitory and histamine H 3 antagonistic activity of piperazine and diazepane amides: QSAR rationales for co-optimization of the activity profiles [DOI]
46. 46 Localization of Tissue Inhibitor of Matrix Metalloproteinases in Alzheimerʼs Disease and Normal Brain [DOI]
47. 47 A METALLOPROTEINASE INHIBITOR BLOCKS THE SHEDDING OF SOLUBLE CYTOKINE RECEPTORS AND PROCESSING OF TRANSMEMBRANE CYTOKINE PRECURSORS IN HUMAN MONOCYTIC CELLS [DOI]
48. 48 Modeling of inhibitor–metalloenzyme interactions and selectivity using molecular mechanics grounded in quantum chemistry [DOI]
49. 49 Novel indolactam-based inhibitors of matrix metalloproteinases [DOI]
50. 50 Determination of metalloproteinases, plasminogenactivators and their inhibitors in the synovial fluids of patients with rheumatoid arthritis during chemical synoviorthesis [DOI]
51. 51 A new look at the statistical model identification [DOI]
52. 52 Variable Selection in QSAR Studies. I. An Evolutionary Algorithm [DOI]
53. 53 Structural Bases for Substrate and Inhibitor Recognition by Matrix Metalloproteinases [DOI]
54. 54 The Design and Synthesis of Aryl Hydroxamic Acid Inhibitors of MMPs and TACE [DOI]
55. 55 Chemometric descriptors in modeling the carbonic anhydrase inhibition activity of sulfonamide and sulfamate derivatives [DOI]
56. 56 The design of selective non-substrate-based matrix metalloproteinase inhibitors.

Cited by 6

Showing 3 of 6 known citations — external sources report more than can currently be individually listed.

Related research

• QSAR Study of Series of HEPT (1-[(2-hydroxyethoxy) methyl]-6-(phenylthio)thyio)thymine) Derivatives Using Genetic Function Approximation as Anti-HIV-1 Agents — shares topic coverage
• In silico Screening of Potential Drug Candidate against Chain a of Coronavirus Binding Protein from Major Nigella Bioactive Compounds — shares topic coverage
• A Quantitative Structure-activity Relationship (QSAR) Study of the Anti-tuberculosis Activity of Some Quinolones — shares topic coverage
• Prediction of the Inhibitory Concentration of Hydroxamic Acids by DFT-QSAR Models on Histone Deacetylase 1 — shares topic coverage
• QSAR Study of 3-Phenylamino-1,4-naphtoquinones Anti-cancer Activities — shares topic coverage